Patient satisfaction fuels the passion of our team, keeping us laser-focused on continuing to grow Dignitana to its full potential.
Increased demand and high customer satisfaction continue to drive Dignitana’s growth. We have a clear strategy to raise awareness, affordbility and accessability that is built on demonstrated efficacy, scalable infrastructure, and competence in medical device and clinical operations. This growth allows us to provide the life-changing DigniCap treatment to even more patients – and that is at the core of our mission.
Net sales in the period showed solid growth with a 36 percent improvement over Q3 2021 and a 38 percent improvement in Average Daily Treatment Revenue (ADTR) versus the same period one year ago.
Dignitana is committed to ensuring that every single cancer patient can maintain dignity and quality of life during and after cancer treatment. Currently 87 percent of our customers are women, so having the opportunity to deliver our message specifically to female investors allows us to really focus on what we know matters to women – both as patients, and as investors in MedTech.
Dignitana already has a solid reputation for providing exemplary support and this new program takes that standard even higher with next level service, training, materials and best practices.
Scalp cooling is evidence-based, recommended by the National Comprehensive Cancer Network® (NCCN), and now supported by the AMA as well. Scalp cooling should become standard of care with universal insurance coverage so that any cancer patient who wishes to minimize hair loss from chemotherapy has access to this life-changing treatment.
As the Company continues an extended growth trajectory, Ulf’ s ability to create value will ensure that we maintain a solid financial foundation as we move toward cash flow positivity.
During these challenging times our company has continued to grow and adapt to the unique and generational challenges we face.
Susan G. Komen is the world’s leading breast cancer organization, providing valuable resources and information to patients worldwide. We are honored to support the important work they do as we continue to increase awareness of scalp cooling in the breast cancer community and beyond.
I am very happy about the opportunity to be part of and lead Dignitana's continued growth journey. There is a great need for scalp cooling worldwide and I hope that my experience can help increase the value for both patients, companies and shareholders.
We welcome Catarina, who with her experience and expertise will take Dignitana into the next growth phase where the focus is on faster expansion and increased profitability.
I appreciate the entrepreneurial spirit of Dignitana and I see many similarities in this company compared to where CellaVision was when I joined that company. Dignitana is a growing company with tremendous potential – it has global reach, an excellent product, and a solid foundation. I am excited about the opportunity and look forward to continuing the good work of the company to improve well-being and the lives of cancer patients.
The strategic expansion of the company is our top priority. We are well-positioned to take advantage of the opportunities before us in the critical US market and around the globe, and the financial and operational experience that Magnus Blixt brings will be a tremendous asset to the Company.
I firmly believe that we have made the right choices and realigned our organization to take the next step towards attaining our long-awaited goal of cash flow positivity.
Medicare coverage is critical to our overall reimbursement efforts and will undoubtedly increase utilization with existing customers and drive demand for DigniCap at new facilities.
This decision ensures that thousands of cancer patients will now have access to life-changing scalp cooling therapy that was previously financially out of reach. It is a major milestone for Dignitana and for so many in the cancer treatment community who have worked tirelessly to make scalp cooling standard of care.
Keeping my hair helped me keep a part of myself that felt strong and centered. It was a blessing in a very difficult time.
When cancer happened to me, I didn’t know what to do or where to turn. I’ll never forget that feeling, and I want to be there for other women who might be feeling the same.
Putting patients first is a priority for Dignitana, and we are honored to recognize these inspirational patient stories through the DigniCap Dignitary program.
My hair is so much a part of who I am,” Agostino said. “This treatment can help so many people. It helped me keep a positive mindset the whole time, and there’s no way that would have been possible for me without keeping my hair.
Dignitana continues our growth trajectory, and the second period of the year provides solid evidence of the progress we are making.
As supplier we strive to provide the best quality devices, and we are very excited to introduce the next generation DigniCap Delta system to the oncology sector in Benelux. Infection prevention is a priority for our customers, and DigniCap effectively addresses this with their unique single patient cap system.
When the AMA announced the CPT codes for scalp cooling last fall, we initiated a plan to do our part to help the oncology community establish appropriate reimbursement. JDL Access and JD Lymon are the ideal partners to help us achieve that.
Our relentless commitment to patient success is the driving force behind everything we do. By maintaining this focus and making scalp cooling a standard of care, I am confident that we will meet our long-term financial goals.
The success of the DigniCap clinical evaluation in Australia has been quite impressive and we are eager to make this technology available to a wider audience. We are committed to providing best in class care for our patients and our partnership with Dignitana provides significant value to our medical oncology patients.
GenesisCare is known for exemplary patient care and we are honored to have them on our growing list of DigniCap providers around the globe. Quality of life is extremely important for cancer patients. As awareness of the efficacy of DigniCap increases, demand for this life-changing treatment is growing as well.
The Company’s agility and adaptability have helped Dignitana to not just survive during the pandemic, but also to thrive as we strategically move toward attaining our operational and financial goals.
Patients from around the world come to Mammazentrum for cutting-edge cancer care. DigniCap is an important part of our integrative approach, helping to preserve a patient’s privacy and self-esteem during a very difficult time.
Mammazentrum is a recognized leader in cancer care and has been a valued Dignitana customer for many years. We are excited to enhance their scalp cooling program with our latest technology. Clinicians in Europe and around the world are seeing first-hand the advantages offered by DigniCap Delta, and the successful outcomes at Mammazentrum are a prime example of this.
At GenesisCare we believe in a holistic approach to cancer care which considers both the physical and emotional needs of our patients. We share Dignitana’s commitment to minimizing the emotional burdens associated with chemotherapy and supporting the psychological health of cancer patients.
With this partnership DigniCap is accessible to thousands more patients who would otherwise face the prospect of losing their hair during chemotherapy. GenesisCare truly is a global leader in oncology and we are thrilled to be working with their experienced and innovative team who share our commitment of putting patients first.
Demand for this important therapy is growing and together we will make scalp cooling a standard in modern cancer care. There is no doubt that scalp cooling is now something that cancer patients want and need to improve their quality of life at a very difficult time.
City of Hope is known for clinical excellence and their commitment to patient care. This expansion has been driven by patient demand in Southern California and the success that patients have with DigniCap. We are thrilled that more patients will now have access this life-changing treatment as we move even closer to scalp cooling becoming a standard of care.
This partnership with Dignitana enables us to improve the patient experience, Our physicians are committed to providing exceptional cancer care. By being able to offer the DigniCap to patients undergoing chemotherapy, we’ll be helping to diminish the added emotional burden from hair loss.
AON provides a unique model of physician-led community oncology that aligns well with our organizational goals, Physicians know that hair loss is a significant quality of life issue and they want to provide DigniCap for their patients. This master contract expedites the administrative process so that more patients can access this life-changing therapy.
As one of India’s fastest growing healthcare companies, MedPhy Technologies is known for providing scientifically proven, safe, and clinically effective medical technology to the country’s most trusted health facilities. It is a privilege to partner with MedPhy to bring DigniCap to India.
The preservation of dignity is critically important to any patient. DigniCap addresses one of the most devastating side effects of chemotherapy, preserving a patient’s dignity at a very vulnerable time. The integration of scalp cooling into comprehensive cancer care in India will play an especially important role in improving well-being among the country’s at-risk patient populations.
Susan G. Komen remains committed to the fight against breast cancer, taking every step we can toward our mission of saving lives and supporting those affected by breast cancer. We are so grateful for supporters like Dignitana and look forward to seeing the impact our partnership will make.
“As the world’s leading nonprofit breast cancer organization, Susan G. Komen launched a movement that has made a worldwide impact in the fight against breast cancer. We are honored to support Susan G. Komen and the important work they do from the community level up.
DigniCap Delta changes everything about the way scalp cooling is done today. Australia is a very important market for us and, as scalp cooling has become a standard of care for patients here, the Delta device will enable our partner sites to offer this valuable therapy option to more patients and much more efficiently.
Clinicians want to help patients maintain a level of privacy and control that is often lost after diagnosis. Helping cancer care teams address quality of life is an essential component of what we do every single day. Our DigniCap Dignitaries are just one more way we provide patients with a highly personalized level of support and care.
Identity, privacy and confidence became important and very personal concerns when I was diagnosed with cancer and put on a chemotherapy regimen. I’m incredibly honored by this opportunity to help others who I’m sure will have tons of questions, just as I did. To have someone who can help you know what to expect is so important. I can’t wait to connect with other cancer patients looking to keep their hair during chemo.
The technological advances engineered into the new DigniCap Delta bring scalp cooling therapy to a whole new level, This streamlined model offers a new gold standard in patient comfort, flexibility and precision fit and is designed for ease of use and efficiency by clinicians.
As the leading innovator in scalp cooling technology we know first-hand the importance of knowledge, early diagnoses and treatment. We welcome initiatives that highlight the quest for supportive cancer care and enhance quality of life options.
We are pleased that this approval comes at a time when both awareness of and demand for scalp cooling are rapidly increasing. The clearance of Delta now provides a clear pathway for growth in the important U.S. market and beyond. It is the biggest step yet in the evolution of Dignitana and is the result of a tremendous effort from our staff, partner sites, regulatory team and contract manufacturer.
DigniCap Delta changes everything about the way scalp cooling is done today. In the value-based U.S. health care system providers tell us they want to improve the clinical process, reduce nursing intervention and optimize patient outcomes. This new device, developed along with our partner sites, allows them to accomplish all three of these objectives. We are thrilled to offer patients and clinicians this state-of-the-art advancement in cancer care.
Dignitana is moving forward with positive momentum. We are confident that the new system will provide clear benefits to hospitals and patients and we look forward to accelerated growth with the launch of this new system in the first half of 2019.
This is a very important first step in our commitment to bring DigniCap to the Asian market in conjunction with our distribution partner Konica Minolta. As of yet there is no data from a clinical study of scalp cooling with an exclusively Asian population. Beijing Cancer Hospital is a leading cancer treatment facility in Asia and we are eager to work with them in this milestone study.
The results we posted this quarter represent a very important milestone for Dignitana. Quarterly revenue for the company reached 9,022 TSEK. With the organizational restructuring we have implemented, the company is close to reaching a breakeven point in regard to our costs for continuing operations.
As Dignitana now moves into a new chapter, the broad and varied expertise of the proposed slate of Thomas Kelly, Ingrid Atteryd Heiman and Mikael Wahlgren will be a tremendous asset to our continued growth and development.